Cerner partners with Salesforce to deliver the next phase of connected healthcare
Cerner has recently announced its partnership with global leader in customer relationship management (CRM), Salesforce at HIMSS18. The collaboration will enable the company to extend its population health, clinical and administration portfolio through a world-class, integrated solution.
Salesforce Health Cloud provides exceptional security through the use of cloud technology. Combining its big data platform, HealtheIntent, with Cerner’s data, analytic and application platform, electronic health record (EHR) and intelligent solutions, its Health Cloud and Marketing Cloud will support the delivery of an enhanced, personalised, and connected patient engagement experience.
“We are entering the next phase of health care delivery transformation. This collaboration with Salesforce will bring game-changing solutions to consumers, allowing them to participate in their physician’s decision-making and engage in their own health and care,” explained Zane Burke, President at Cerner.
“We have digitised EHRs and are now aggregating and enriching this data for clinical and engagement insights through applied intelligence. The next phase is to modernise the way our industry personalises and interacts with people in their communities. The power of these combined technologies will support an improved consumer experience and enhanced clinician communication, as well as materially advance the quality of care while reducing the total cost.”
Through the partnership, Cerner aims to meet the growing demand for enterprise-wide CRM capabilities within the healthcare space. Salesforce Health Cloud will therefore further drive collaboration and support health providers to gain a greater understanding and awareness of patient needs, which will drive positive health outcomes.
- WHOOP raises $25mn in Series C funding
- Lyft launches its own non-emergency transportation service, set to rival UberHealth
- Avoidance of financial penalties remains a top driver for US healthcare security spend
Powered by the data and clinical content within Cerner HealtheIntent, the platform will aggregate data in near real-time from multiple sources to create a single, comprehensive view of an individual’s health interactions across the continuum of health and care. This will enable the creation of actionable insights which can be integrated into the clinical workflow.
The solution is also positioned to support health system call centers, service operations, provider network management, marketing and other enterprise stakeholders that are transforming how services are delivered to patients and providers through a growing array of communication channels.
"The health care industry is undergoing a powerful transformation. Patients are bringing new expectations to their experiences — they want providers to deliver better service on their terms," added Keith Block, Vice Chairman, President and COO at Salesforce.
“The powerful combination of Salesforce and Cerner technology will empower providers to connect with patients in smarter and more personalised ways, and ultimately deliver better outcomes."
Promoting provider communication and collaboration, these omnichannel capabilities will incorporate a range of digital tools and management programs. The integrated solution will also enhance the value of call centers, practice management, patient financial services and other health care provider service operations.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.